Olaratumab for the treatment of advanced soft tissue sarcoma

Research output: Contribution to journalArticle

Abstract

Introduction: Olaratumab, a human monoclonal antibody against platelet derived growth factor receptor alpha (PDGFR- α), is the first drug that in combination with doxorubicin for the treatment of patients with advanced/metastatic soft tissue sarcoma (STS) that has showed an improved overall survival compared to doxorubicin alone. These initial results are exciting and have the potential to change the landscape of treatment for patients with STS. Areas covered: This article reviews the development of olaratumab for oncology use by reviewing articles in PubMed for ‘platelet derived growth factor’ and ‘receptor’ and ‘soft tissue sarcoma’. We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. Expert commentary: Olaratumab is a well-tolerated drug that, when combined with doxorubicin, has shown an improved overall survival compared to doxorubicin alone and the phase III confirmatory study is eagerly awaited.

Original languageEnglish (US)
Pages (from-to)883-887
Number of pages5
JournalExpert Review of Anticancer Therapy
Volume17
Issue number10
DOIs
StatePublished - Oct 3 2017

Fingerprint

Sarcoma
Doxorubicin
Platelet-Derived Growth Factor alpha Receptor
Platelet-Derived Growth Factor Receptors
Survival
Drug Combinations
Therapeutics
PubMed
Monoclonal Antibodies
olaratumab
Pharmaceutical Preparations

Keywords

  • chemotherapy
  • olaratumab
  • platelet derived growth factor
  • platelet derived growth factor receptor
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Olaratumab for the treatment of advanced soft tissue sarcoma. / Okuno, Scott Heitaka; Maran, Avudaiappan; Robinson, Steven.

In: Expert Review of Anticancer Therapy, Vol. 17, No. 10, 03.10.2017, p. 883-887.

Research output: Contribution to journalArticle

@article{5225d443b94e42f985bb4798d87a3d90,
title = "Olaratumab for the treatment of advanced soft tissue sarcoma",
abstract = "Introduction: Olaratumab, a human monoclonal antibody against platelet derived growth factor receptor alpha (PDGFR- α), is the first drug that in combination with doxorubicin for the treatment of patients with advanced/metastatic soft tissue sarcoma (STS) that has showed an improved overall survival compared to doxorubicin alone. These initial results are exciting and have the potential to change the landscape of treatment for patients with STS. Areas covered: This article reviews the development of olaratumab for oncology use by reviewing articles in PubMed for ‘platelet derived growth factor’ and ‘receptor’ and ‘soft tissue sarcoma’. We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. Expert commentary: Olaratumab is a well-tolerated drug that, when combined with doxorubicin, has shown an improved overall survival compared to doxorubicin alone and the phase III confirmatory study is eagerly awaited.",
keywords = "chemotherapy, olaratumab, platelet derived growth factor, platelet derived growth factor receptor, Soft tissue sarcoma",
author = "Okuno, {Scott Heitaka} and Avudaiappan Maran and Steven Robinson",
year = "2017",
month = "10",
day = "3",
doi = "10.1080/14737140.2017.1374857",
language = "English (US)",
volume = "17",
pages = "883--887",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Olaratumab for the treatment of advanced soft tissue sarcoma

AU - Okuno, Scott Heitaka

AU - Maran, Avudaiappan

AU - Robinson, Steven

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Introduction: Olaratumab, a human monoclonal antibody against platelet derived growth factor receptor alpha (PDGFR- α), is the first drug that in combination with doxorubicin for the treatment of patients with advanced/metastatic soft tissue sarcoma (STS) that has showed an improved overall survival compared to doxorubicin alone. These initial results are exciting and have the potential to change the landscape of treatment for patients with STS. Areas covered: This article reviews the development of olaratumab for oncology use by reviewing articles in PubMed for ‘platelet derived growth factor’ and ‘receptor’ and ‘soft tissue sarcoma’. We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. Expert commentary: Olaratumab is a well-tolerated drug that, when combined with doxorubicin, has shown an improved overall survival compared to doxorubicin alone and the phase III confirmatory study is eagerly awaited.

AB - Introduction: Olaratumab, a human monoclonal antibody against platelet derived growth factor receptor alpha (PDGFR- α), is the first drug that in combination with doxorubicin for the treatment of patients with advanced/metastatic soft tissue sarcoma (STS) that has showed an improved overall survival compared to doxorubicin alone. These initial results are exciting and have the potential to change the landscape of treatment for patients with STS. Areas covered: This article reviews the development of olaratumab for oncology use by reviewing articles in PubMed for ‘platelet derived growth factor’ and ‘receptor’ and ‘soft tissue sarcoma’. We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. Expert commentary: Olaratumab is a well-tolerated drug that, when combined with doxorubicin, has shown an improved overall survival compared to doxorubicin alone and the phase III confirmatory study is eagerly awaited.

KW - chemotherapy

KW - olaratumab

KW - platelet derived growth factor

KW - platelet derived growth factor receptor

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85029445162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029445162&partnerID=8YFLogxK

U2 - 10.1080/14737140.2017.1374857

DO - 10.1080/14737140.2017.1374857

M3 - Article

C2 - 28862476

AN - SCOPUS:85029445162

VL - 17

SP - 883

EP - 887

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 10

ER -